Masimo (NASDAQ:MASI) Updates FY 2025 Earnings Guidance

Masimo (NASDAQ:MASI) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 4.900-5.100 for the period, compared to the consensus estimate of 4.670. The company issued revenue guidance of -. Masimo also updated its FY 2024 guidance to 4.100-4.100 EPS.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. BTIG Research raised their target price on Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Stifel Nicolaus reissued a “buy” rating and issued a $190.00 price objective (up from $170.00) on shares of Masimo in a report on Friday, November 22nd. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research note on Thursday. Raymond James lifted their price target on shares of Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research note on Friday, December 27th. Finally, Wells Fargo & Company boosted their price target on shares of Masimo from $171.00 to $193.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $179.67.

Masimo Price Performance

MASI stock opened at $172.29 on Friday. Masimo has a 1 year low of $101.61 and a 1 year high of $180.97. The firm has a market capitalization of $9.22 billion, a PE ratio of 118.82 and a beta of 1.01. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. The business has a 50 day simple moving average of $169.23 and a 200-day simple moving average of $140.13.

Masimo (NASDAQ:MASI) last issued its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.84 by $0.14. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The company had revenue of $504.60 million during the quarter, compared to analysts’ expectations of $502.87 million. During the same period in the prior year, the business earned $0.63 EPS. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. Equities research analysts anticipate that Masimo will post 4.03 earnings per share for the current fiscal year.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.